Both in Pharmaceuticals
Cue Biopharma vs Atrium Therapeutics
Over the past year CUE returned −3.1% and RNA returned −87.5%; their daily moves had a correlation of 0.02.
CUE −3.1% RNA −87.5%Growth of $1, one year, split-adjusted
| Metric | CUE | RNA |
|---|---|---|
| Price | $20.86 | $8.72 |
| Market cap | $151.5M | $149.2M |
| Today | +7.42% | +1.99% |
| 1 month | −14.4% | +9.4% |
| 6 months | −40.3% | −32.5% |
| Year to date | +127.7% | −87.9% |
| 1 year | −9.4% | — |
| Revenue growth (YoY) | +166.7% | −21.9% |
| Gross margin | 100.0% | 100.0% |
| Net margin | −1943.2% | −672.0% |
| P/E (TTM) | — | — |
| Price / sales | 4.0× | 4.1× |
| Net cash | $16.4M | $263.9M |
| Dividend yield | — | — |
| Volatility (60d) | 138.5% | 65.8% |
| Short % of float | 12.2% | 22.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).